Related coverage linked through entity extraction aliases.
Jul 14, 2026
Acurx Pharmaceuticals announced that ibezapolstat preserves beneficial gut microbes in multiply-recurrent C. difficile infection and outperforms standard antibiotics in biofilm killing. A pilot trial in rCDI is set to begin, with plans for FDA approval under the Limited Population Pathway if successful.
Jun 16, 2026
Acurx Pharmaceuticals is advancing ibezapolstat to international Phase 3 clinical trials for C. difficile infection following final regulatory guidance from FDA and EMA. The company launched a new clinical trial program for recurrent CDI and presented structural biology research demonstrating ibezapolstat's mechanism of action. Acurx reported year-end 2025 cash of $7.6 million.
Apr 01, 2026
CRS3123, an investigational antibiotic for C. difficile infection, demonstrated 97% clinical cure rates and significantly lower recurrence (4% vs 23% for vancomycin) in a Phase 2 trial. The narrow-spectrum drug better preserves gut microbiome health and secondary bile acid synthesis compared to standard vancomycin treatment. These positive results support advancing CRS3123 into Phase 3 development.
Mar 03, 2026
Acurx Pharmaceuticals will discuss full year and fourth quarter 2025 financial results on March 13, 2026, and provide updates on ibezapolstat, its lead antibiotic candidate preparing for international Phase 3 trials for C. difficile infection.
